2/2/2023 4:39:12 PM
Rigel : REZLIDHIA Induces Durable Remissions In Adult Patients With MIDH1 Relapsed Or Refractory Acute Myeloid Leukemia
1/9/2023 8:10:30 AM
Rigel Pharma Reports Preliminary Q4 Total Revenue Of About $51.3 Mln
12/22/2022 8:26:37 AM
Rigel To Launch REZLIDHIA Thursday In U.S. For Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
12/15/2022 8:09:54 AM
Rigel Pharma Doses First Patient In Phase 1b Study Of R289 For Treatment Of Lower-Risk Myelodysplastic Syndromes
11/3/2022 4:03:21 PM
Rigel Pharma Q3 Loss/share $0.11 Vs. Loss $0.12 Year Ago
8/2/2022 4:11:57 PM
Rigel Pharma Q2 Loss/share $0.08, Same As Last Year
6/8/2022 7:02:44 AM
Rigel Says FORWARD Phase 3 Trial Of Fostamatinib Did Not Demonstrate Statistical Significance In Primary Endpoint